<DOC>
	<DOC>NCT00354874</DOC>
	<brief_summary>This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444. This will be a multi-centre, double-blind, placebo controlled, dose ascending, four way cross-over study in approximately 28 mild to moderate asthmatic subjects. Key assessments: Efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics will be assessed by measurement of FEV1, blood pressure, heart rate, 12-lead ECGs, clinical laboratory tests, collection of adverse events (AE) information and blood samples.</brief_summary>
	<brief_title>Investigation Of A New Medication (GW642444) In Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Female subjects must be nonchildbearing (i.e., surgically sterilised or postmenopausal). Nonsmokers for at least 6 months. Stable asthma. Exclusion criteria: Abnormal findings on heart monitoring assessment. Lower respiratory tract infection within 4 weeks, upper respiratory tract within 2 weeks of study. Currently taking doses of fluticasone propionate over 500mcg/day. Unstable asthma medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GW642444 asthmatic subjects safety tolerability PD and PK</keyword>
</DOC>